CONRAD Statement on MDP 301 Results

December 14, 2009

Main study results of the MDP 301 Phase III clinical trial of 0.5% PRO 2000 gel shows conclusively that the microbicide does not prevent HIV infection in women.  While there were no safety concerns in the trial of 9,385 women, the gel does not prevent infection when compared to a placebo.  These results are not incompatible with an earlier study of 0.5% PRO 2000 in 3,099 women conducted by the HIV Prevention Trials Network and the Microbicide Trials Network.   This study found that women who were randomly assigned to use PRO 2000 and condoms were 30% less likely to become infected with HIV than women assigned to use a placebo gel.  These results were encouraging, but not statistically significant and additional clinical evidence in a larger population of women was necessary for providing conclusive evidence of effectiveness.

CONRAD praises the dedication of the trial participants and the Microbicide Development Programme team for running an excellent trial.  While the results are disappointing, we are hopeful that ongoing studies of tenofovir gel, currently being conducted by CAPRISA in Durban, South Africa, and the VOICE trial of both tenofovir gel and oral antiretrovirals, conducted by the Microbicide Trials Network, will push our progress forward in preventing HIV infection. 

We at CONRAD continue to believe that providing a variety of HIV prevention methods that are female initiated is crucial to decreasing new HIV infections, particularly in developing nations.  We will continue to collaborate with our funders and partners to research and develop these medicines and devices.

1911 North Fort Myer Drive, Suite 900, Arlington, Virginia 22209   T: (703) 524-4744 |